CAR T-cell Therapy
Kappa CD28 T Cells for Leukemia
This trial is testing a new treatment for patients with a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment. The treatment is a gene transfer research study using special immune cells. The study is testing whether combining two different ways of fighting disease, antibodies and T cells, will be more effective than using either method alone.
Cell Therapy
Stem Cell Transplant for Blood Cancers
This trial is testing a new stem cell transplantation method for people with blood cancers. The new method uses a machine to remove certain cells from the donor stem cells, and it also removes a different type of cell from the patient before transplant. The trial will measure how well the transplant works and how long the patient survives without the cancer coming back.
Popular Filters
Trials for Burkitt Lymphoma Patients
CAR T-cell Therapy
Genetically Modified T cells for Leukemia and Lymphoma
This trial is testing the safety of giving patients modified T-cells from a donor. The goal is to see if these cells cause any toxicities in patients with relapsed B cell leukemia or lymphoma.
Monoclonal Antibodies
Combination Therapy for Mantle Cell Lymphoma
This trial is studying a combination of rituximab, bortezomib, bendamustine, and lenalidomide to see how well it works compared with rituximab and bendamustine, followed by rituximab alone or with lenalidomide, in treating mantle cell lymphoma.
Trials for Follicular Lymphoma Patients
CAR T-cell Therapy
Genetically Modified T cells for Leukemia and Lymphoma
This trial is testing the safety of giving patients modified T-cells from a donor. The goal is to see if these cells cause any toxicities in patients with relapsed B cell leukemia or lymphoma.
Monoclonal Antibodies
Combination Therapy for Mantle Cell Lymphoma
This trial is studying a combination of rituximab, bortezomib, bendamustine, and lenalidomide to see how well it works compared with rituximab and bendamustine, followed by rituximab alone or with lenalidomide, in treating mantle cell lymphoma.
Trials for CD30 Positive Patients
CAR T-cell Therapy
CAR-T Cell Therapy for Lymphoma
This trial tests a new treatment using lab-modified immune cells to target and kill cancer cells in patients with certain types of lymphoma that haven't responded to other treatments. The modified cells are designed to better locate and destroy cancer cells. This new approach extends the capacity of the patient's own immune cells to detect and eliminate cancer cells.
CAR T-cell Therapy
Immunotherapy for Lymphoma
This trial tests a new treatment where a patient's immune cells are enhanced to better fight cancer. It targets adults whose CD30+ cancer has come back or resisted other treatments. The enhanced cells are designed to specifically attack cancer cells, making the immune system more effective against the disease.
Trials With No Placebo
CAR T-cell Therapy
Genetically Modified T cells for Leukemia and Lymphoma
This trial is testing the safety of giving patients modified T-cells from a donor. The goal is to see if these cells cause any toxicities in patients with relapsed B cell leukemia or lymphoma.
Monoclonal Antibodies
Combination Therapy for Mantle Cell Lymphoma
This trial is studying a combination of rituximab, bortezomib, bendamustine, and lenalidomide to see how well it works compared with rituximab and bendamustine, followed by rituximab alone or with lenalidomide, in treating mantle cell lymphoma.
View More Related Trials
Frequently Asked Questions
Introduction to lymphoma
What are the top hospitals conducting lymphoma research?
When it comes to cutting-edge clinical trials in the field of lymphoma, several top hospitals are making significant strides. In New york City, the Memorial Sloan Kettering Cancer Center stands out with an impressive 10 active trials focused on lymphoma and a remarkable 238 completed studies throughout their history. This esteemed institution first ventured into lymphoma research back in 1995, demonstrating their longstanding commitment to understanding and treating this complex disease.
Meanwhile, on the East Coast in Boston, another renowned hospital is contributing greatly to lymphoma research. The Dana Farber Cancer Institute currently has seven active clinical trials dedicated to lymphoma and a noteworthy track record of 108 completed studies since initiating their first trial in 2000. Their expertise and dedication have made them a key player in advancing our knowledge of this challenging condition.
In Houston, Texas, two prestigious institutions are at the forefront of innovative lymphoma trials. The MD Anderson Cancer Center boasts six active clinical trials focused specifically on lymphoma treatment options while having conducted an impressive total of 144 previous investigations since launching its inaugural trial in 2001. Another branch of MD Anderson Cancer Center located within Houston also showcases similar dedication towards combating this disease with six ongoing explorations complemented by149 previously held trials dating back as early as1998.
On the West Coast lies Cedars-Sinai Medical Center situated in Los Angeles—a crucial contributor to advancing our understanding of lymphomas through diligent efforts and relentless innovation over time; they presently undertake four progressive clinical examinations alongside twenty-two prior endeavors—inaugurating their foray into these important investigations from as far back as1997.
These leading hospitals across different regions demonstrate a shared goal: pushing boundaries and seeking breakthroughs that can ultimately improve outcomes for those affected by lymphomas worldwide. By participating actively in these groundbreaking clinical trials, patients gain access to potentially life-saving treatments while paving the path for future advancements against this formidable disease
Which are the best cities for lymphoma clinical trials?
When it comes to lymphoma clinical trials, several cities stand out as hubs for cutting-edge research and treatment development. Houston, Texas leads the way with 35 active trials focusing on various treatments such as maplirpacept (PF-07901801) + an anti-CD20 targeting agent and EBV-specific T cells. Los Angeles, California follows closely behind with 25 ongoing studies exploring innovative approaches like maplirpacept (PF-07901801) + an anti-CD20 targeting agent and subprotocol C2 for MET exon 14 deletion/mutation. New york City also plays a significant role with 22 active trials investigating treatments including maplirpacept (PF-07901801) + an anti-CD20 targeting agent and ASTX660. These cities, along with Boston, Massachusetts (20 active trials) and Denver, Colorado (17 active trials), offer individuals facing lymphoma access to advanced clinical trials that pave the way for improved care options and better outcomes.
Which are the top treatments for lymphoma being explored in clinical trials?
Exciting advancements in lymphoma research are being made through rigorous clinical trials. Leading the way is rituximab, a well-established treatment with two active trials and an impressive history of 215 all-time lymphoma studies since its introduction in 1997. Additionally, another form of rituximab is also showing promise, currently involved in two ongoing trials and having been extensively studied with 588 all-time lymphoma trials since 1993. A newcomer on the scene is Biomarker Guided Intervention, which has shown potential in one active trial so far but holds great promise for future breakthroughs. These innovative treatments offer hope to patients battling this challenging disease and inspire optimism about improved outcomes in the years to come.
What are the most recent clinical trials for lymphoma?
Exciting advancements in the field of lymphoma research provide hope for improved treatment options. Prominent among the recent clinical trials is a Phase 1/Phase 2 study exploring dose escalation strategies to enhance therapeutic outcomes. Additionally, an innovative approach involving anti-CD30 bispecific antibody-armed anti-CD3 activated autologous T-cells (CD30 biAb-AATC) shows promise in targeting lymphoma cells specifically. Moreover, ongoing investigations into the efficacy and safety of Heplisav-B offer potential benefits for individuals with lymphoma. Another area of focus is stereotactic body radiation therapy, which aims to optimize treatment delivery and minimize side effects. Lastly, Glofitamab demonstrates its potential as a valuable therapeutic option through a comprehensive Phase 2 trial. These diverse studies pave the way towards more effective interventions and better prognoses for those affected by lymphoma.
What lymphoma clinical trials were recently completed?
Multiple clinical trials for lymphoma have recently reached significant milestones, signaling progress in the search for more effective treatments. In September 2021, the University of Chicago completed a trial investigating CC-486 as a potential therapy option. Additionally, the National Cancer Institute concluded their study on mRNA-1273 in April 2021. Moreover, the University of Colorado, Denver wrapped up their trial exploring Ublituximab in November 2020. These recent advancements highlight ongoing efforts by researchers to advance treatment options and provide hope for individuals battling lymphoma.